Delving into the Latest Updates on HLK-5003 with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

HLK-5003

Target-

Action-

Mechanism-

Therapeutic Areas

Infectious DiseasesSkin and Musculoskeletal Diseases

Active Indication

Onychomycosis

Inactive Indication-

Originator Organization

Shenzhen Pharmacin Co., Ltd

Active Organization

Shenzhen Pharmacin Co., Ltd

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的：评价HLK-5003涂膜剂在轻、中度甲真菌病患者中的安全性和耐受性次要目的：1) 评价HLK-5003涂膜剂在轻、中度甲真菌病患者中的药代动力学特征；2) 初步评价HLK-5003涂膜剂在轻、中度甲真菌病患者中的有效性，探索HLK-5003在轻、中度甲真菌病患者中的最佳剂量，为后期临床试验提供依据。

[Translation]

Primary Objective: To evaluate the safety and tolerability of HLK-5003 film-coated onychomycosis in patients with mild to moderate onychomycosis. Secondary Objectives: 1) To evaluate the pharmacokinetic characteristics of HLK-5003 film-coated onychomycosis in patients with mild to moderate onychomycosis; 2) To preliminarily evaluate the efficacy of HLK-5003 film-coated onychomycosis in patients with mild to moderate onychomycosis, and to explore the optimal dose of HLK-5003 in these patients, providing a basis for subsequent clinical trials.

Start Date-

Sponsor / Collaborator